Rheumatoid arthritis: Can the long-term outcome be altered?

S. E. Gabriel, H. S. Luthra

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Although several agents (for example, intramuscularly administered gold, auranofin, D-penicillamine, hydroxychloroquine, and methotrexate) are of clinical benefit in the management of rheumatoid arthritis (RA), their effect on the long-term outcome of the disease is controversial. Assessment of the influence of therapeutic interventions in RA is difficult because the natural history of the disease remains poorly defined and unpredictable, and neither the traditional clinical and laboratory measurements of inflammation nor radiographic analyses of progression of joint destruction provide an accurate estimate of the long-term outcome of RA. Furthermore, there is little evidence that second-line agents yield benefits beyond 3 years. Therefore, adequately tested comprehensive measures should be used in large, long-term, multicenter controlled clinical trials to determine whether the long-term outcome of RA can be altered.

Original languageEnglish (US)
Pages (from-to)58-68
Number of pages11
JournalMayo Clinic Proceedings
Volume63
Issue number1
StatePublished - 1988

Fingerprint

Rheumatoid Arthritis
Auranofin
Hydroxychloroquine
Penicillamine
Controlled Clinical Trials
Methotrexate
Gold
Joints
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gabriel, S. E., & Luthra, H. S. (1988). Rheumatoid arthritis: Can the long-term outcome be altered? Mayo Clinic Proceedings, 63(1), 58-68.

Rheumatoid arthritis : Can the long-term outcome be altered? / Gabriel, S. E.; Luthra, H. S.

In: Mayo Clinic Proceedings, Vol. 63, No. 1, 1988, p. 58-68.

Research output: Contribution to journalArticle

Gabriel, SE & Luthra, HS 1988, 'Rheumatoid arthritis: Can the long-term outcome be altered?', Mayo Clinic Proceedings, vol. 63, no. 1, pp. 58-68.
Gabriel, S. E. ; Luthra, H. S. / Rheumatoid arthritis : Can the long-term outcome be altered?. In: Mayo Clinic Proceedings. 1988 ; Vol. 63, No. 1. pp. 58-68.
@article{9b1a7ad44ece4c3ea72313dd5e6f837a,
title = "Rheumatoid arthritis: Can the long-term outcome be altered?",
abstract = "Although several agents (for example, intramuscularly administered gold, auranofin, D-penicillamine, hydroxychloroquine, and methotrexate) are of clinical benefit in the management of rheumatoid arthritis (RA), their effect on the long-term outcome of the disease is controversial. Assessment of the influence of therapeutic interventions in RA is difficult because the natural history of the disease remains poorly defined and unpredictable, and neither the traditional clinical and laboratory measurements of inflammation nor radiographic analyses of progression of joint destruction provide an accurate estimate of the long-term outcome of RA. Furthermore, there is little evidence that second-line agents yield benefits beyond 3 years. Therefore, adequately tested comprehensive measures should be used in large, long-term, multicenter controlled clinical trials to determine whether the long-term outcome of RA can be altered.",
author = "Gabriel, {S. E.} and Luthra, {H. S.}",
year = "1988",
language = "English (US)",
volume = "63",
pages = "58--68",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Rheumatoid arthritis

T2 - Can the long-term outcome be altered?

AU - Gabriel, S. E.

AU - Luthra, H. S.

PY - 1988

Y1 - 1988

N2 - Although several agents (for example, intramuscularly administered gold, auranofin, D-penicillamine, hydroxychloroquine, and methotrexate) are of clinical benefit in the management of rheumatoid arthritis (RA), their effect on the long-term outcome of the disease is controversial. Assessment of the influence of therapeutic interventions in RA is difficult because the natural history of the disease remains poorly defined and unpredictable, and neither the traditional clinical and laboratory measurements of inflammation nor radiographic analyses of progression of joint destruction provide an accurate estimate of the long-term outcome of RA. Furthermore, there is little evidence that second-line agents yield benefits beyond 3 years. Therefore, adequately tested comprehensive measures should be used in large, long-term, multicenter controlled clinical trials to determine whether the long-term outcome of RA can be altered.

AB - Although several agents (for example, intramuscularly administered gold, auranofin, D-penicillamine, hydroxychloroquine, and methotrexate) are of clinical benefit in the management of rheumatoid arthritis (RA), their effect on the long-term outcome of the disease is controversial. Assessment of the influence of therapeutic interventions in RA is difficult because the natural history of the disease remains poorly defined and unpredictable, and neither the traditional clinical and laboratory measurements of inflammation nor radiographic analyses of progression of joint destruction provide an accurate estimate of the long-term outcome of RA. Furthermore, there is little evidence that second-line agents yield benefits beyond 3 years. Therefore, adequately tested comprehensive measures should be used in large, long-term, multicenter controlled clinical trials to determine whether the long-term outcome of RA can be altered.

UR - http://www.scopus.com/inward/record.url?scp=0023848389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023848389&partnerID=8YFLogxK

M3 - Article

C2 - 3275843

AN - SCOPUS:0023848389

VL - 63

SP - 58

EP - 68

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -